- Home
- NRXP vs RVPH Comparison
NRXP vs RVPH Comparison
Compare NRXP & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- RVPH
- Stock Information
- Founded
- NRXP 2015
- RVPH 2006
- Country
- NRXP United States
- RVPH United States
- Employees
- NRXP N/A
- RVPH N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- NRXP Health Care
- RVPH Health Care
- Exchange
- NRXP Nasdaq
- RVPH Nasdaq
- Market Cap
- NRXP 32.6M
- RVPH 36.7M
- IPO Year
- NRXP N/A
- RVPH N/A
- Fundamental
- Price
- NRXP $2.90
- RVPH $0.81
- Analyst Decision
- NRXP Strong Buy
- RVPH Strong Buy
- Analyst Count
- NRXP 4
- RVPH 5
- Target Price
- NRXP $28.50
- RVPH $9.00
- AVG Volume (30 Days)
- NRXP 378.9K
- RVPH 600.3K
- Earning Date
- NRXP 05-15-2025
- RVPH 05-15-2025
- Dividend Yield
- NRXP N/A
- RVPH N/A
- EPS Growth
- NRXP N/A
- RVPH N/A
- EPS
- NRXP N/A
- RVPH N/A
- Revenue
- NRXP N/A
- RVPH N/A
- Revenue This Year
- NRXP N/A
- RVPH N/A
- Revenue Next Year
- NRXP N/A
- RVPH N/A
- P/E Ratio
- NRXP N/A
- RVPH N/A
- Revenue Growth
- NRXP N/A
- RVPH N/A
- 52 Week Low
- NRXP $1.10
- RVPH $0.49
- 52 Week High
- NRXP $6.01
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- NRXP 66.47
- RVPH 44.29
- Support Level
- NRXP $2.55
- RVPH $0.78
- Resistance Level
- NRXP $2.72
- RVPH $1.15
- Average True Range (ATR)
- NRXP 0.24
- RVPH 0.10
- MACD
- NRXP 0.02
- RVPH -0.02
- Stochastic Oscillator
- NRXP 80.00
- RVPH 9.37
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.